Natera Prenatal Testing Settlement
Up to the amount paid out of pocket for the test
What happened
Natera allegedly violated certain laws in connection with sales of its noninvasive prenatal screening tests under the names Panorama or Vasistera. Natera denies any wrongdoing and denies violating any law. The parties agreed to settle to avoid the uncertainties and expenses of continued litigation.
Do you qualify?
Anyone who paid out of pocket (including copay, co-insurance, or deductible) for a Natera noninvasive prenatal screening test under the names Panorama or Vasistera while living in the United States during the class period. Class period dates vary by state: Ohio (February 17, 2016 - August 7, 2025), New Jersey (May 5, 2016 - August 7, 2025), Florida (February 24, 2017 - August 7, 2025), New York and Illinois (April 27, 2017 - August 7, 2025), and all other states (February 17, 2018 - August 7, 2025).
How to file
Submit a Claim Form online at the settlement website. You must provide information about your out-of-pocket payment for the Natera test. The deadline to submit your claim is July 24, 2026. When you submit a claim, you give up your right to sue Natera for the claims released by this settlement.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More drugs & medical settlements
View all →QVAR Antitrust Settlement
Teva allegedly violated antitrust laws by improperly listing patents in the FDA's Orange Book and engaging in product hopping to delay generic competition for QVAR and QVAR Redihaler inhalers, causing consumers and third-party payors to overpay for the brand-name drug. Teva denies all allegations and maintains it did nothing wrong.
Tracleer Litigation Settlement
The defendants allegedly unlawfully delayed the entry of generic formulations of bosentan into the market, causing third-party payors to pay more for brand Tracleer and bosentan than they should have. Defendants deny wrongdoing and there has been no court determination that the allegations were proven or caused harm.
Metformin Marketing and Sales Practices Settlement
The defendants falsely advertised their generic metformin drugs as equivalent to Glucophage and Glucophage XR, but the drugs were contaminated with NDMA and did not meet FDA standards. Consumers and businesses paid for drugs they would not have purchased had they known the truth. The defendants deny wrongdoing.
Anthem Grandfathered Rx Settlement
Anthem denied coverage for brand name (single source) prescription drugs and/or applied a deductible to these drugs under certain grandfathered health plans, resulting in out-of-pocket expenses for members and charging some members an $8,850 deductible. The California Department of Insurance required Anthem to settle this matter.
Up to $8,850